Invest1 publisher2 min readPublished
Merger review in a bolt-on deal reaches every fund the sponsor controls
A lawyer who advises on merger filings writes that overlap from repeated bolt-ons builds faster than deal teams price it, and that a remedy can force the sale of an asset sitting in another of the sponsor's funds.
The Investor · Invest desk
What happened
- A merger-filings lawyer writes that bolt-on deals arrive at the Fair Trade Commission with a Plan A and with Plans B, C and D assembled from favorable passages in past decisions.
- The bolt-on structure buys companies in the same or adjacent businesses and adds them to an existing portfolio, which suits funds that must deliver results inside a limited investment period.
- Where the commission finds competition concerns, it can make approval conditional on asset sales or on restrictions on how the business operates.
- The column says private equity buyers have relatively little experience of taking an in-depth review to the end and contesting findings of competitive harm and the remedies attached to them.
- Its recommendation is that merger review be examined at the earliest stage of investment review instead of being handled as a final closing step.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- constraint Accumulation runs one way inside a hold period, so a sponsor's fourth or fifth bolt-on in a sector is the one whose approval odds were set by the first three.
- exposure Limited partners in an older fund can be asked to give up an asset to clear a transaction they never underwrote, at a date chosen by a regulator rather than by their manager.
- decision If the timetable is fixed at signature, the choice moves upstream into the investment screen, where the alternative to a heavily conditioned bid is not bidding.
- cost A long behavioural remedy has to be administered by a manager whose fund needs an exit, and the compliance work continues after the deal that caused it has been sold.
Sequencing is what turns this into a pricing question. The first adjacent acquisition adds share to one portfolio company. The next is measured against the combined position. The column's claim is that overlap with existing portfolio companies pushes share and concentration up quickly as deals accumulate [4]. Bolt-ons appeal to private equity precisely because a fund has to show results inside a limited investment period [3]. The deals that are hardest to clear are the later ones in the sequence [17].
The review reaches past the fund writing the cheque. It covers all portfolio companies controlled by the same general partner [10]. An asset sale ordered as a condition of approval can therefore land on holdings in a different fund, with different limited partners and a different exit date. The column says structural remedies of that kind are difficult in practical terms given how private equity funds are built [11]. Behavioural remedies are the alternative, and the column calls long-running restrictions on another fund's business activities a heavy operational burden [11]. The writer's sense from practice is that the Fair Trade Commission watches for two things. One is whether a fund will act more aggressively in pursuit of short-term results. The other is whether it can reliably comply with long-term remedies [12].
Market definition, competitive pressure, the likelihood of new entry, buyer bargaining power and efficiency claims: five prepared defence lines [6][7], which the column says can be rejected one after another until not a single card remains [6]. "In merger review, having many arguments does not necessarily improve the chances of approval," the lawyer wrote [8].
The column does not include any figures on delayed deals, share thresholds or review durations [18]. That leaves at least two other readings intact. One is that deal teams price review risk about right and choose to carry it. In a contested auction, a bid that reserves for a divestiture loses to one that does not, and the reserve is only worth holding if the buyer expects to be the marginal bidder. The other is that the exposure sits with a handful of sponsors whose portfolios already overlap. If so, the question worth asking is which sponsors those are.
There is also the writer's position to weigh: a lawyer who advises mainly on merger filings [1] concludes that filings analysis belongs at the earliest stage of investment review [13]. That does not make the argument wrong, and the structural point about general-partner-level scope is the part that a sponsor cannot argue its way out of after signing. "The questions the FTC will ask should have been asked before signing," the column said [19].
What to watch
- The first case in which the Fair Trade Commission conditions a bolt-on approval on selling an asset held by a different fund of the same general partner.
- Any published Fair Trade Commission data on in-depth review counts or durations for private equity bolt-on filings, which the column does not supply.
- Whether sponsors start writing longer conditionality and long-stop dates into bolt-on purchase agreements at signing.